Favorable Media Coverage Somewhat Unlikely to Impact GW Pharmaceuticals PLC- (GWPH) Stock Price

Press coverage about GW Pharmaceuticals PLC- (NASDAQ:GWPH) has trended positive on Tuesday, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. GW Pharmaceuticals PLC- earned a news sentiment score of 0.33 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.230614637157 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

These are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:

Shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) traded down $0.23 on Tuesday, reaching $122.32. 270,309 shares of the company were exchanged, compared to its average volume of 330,876. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.59 and a quick ratio of 7.47. GW Pharmaceuticals PLC- has a 12-month low of $92.65 and a 12-month high of $136.95.

A number of analysts recently weighed in on the stock. Cantor Fitzgerald set a $208.00 price objective on shares of GW Pharmaceuticals PLC- and gave the stock a “buy” rating in a report on Monday, December 4th. Goldman Sachs Group reaffirmed a “neutral” rating and issued a $124.00 price objective on shares of GW Pharmaceuticals PLC- in a report on Friday, October 6th. Bank of America dropped their price objective on shares of GW Pharmaceuticals PLC- from $160.00 to $158.00 and set a “buy” rating on the stock in a report on Tuesday, November 14th. ValuEngine raised shares of GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Finally, Evercore ISI assumed coverage on shares of GW Pharmaceuticals PLC- in a report on Wednesday, August 16th. They issued an “outperform” rating and a $154.00 price objective on the stock. One research analyst has rated the stock with a sell rating, four have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $144.55.

COPYRIGHT VIOLATION NOTICE: This news story was first published by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.com-unik.info/2017/12/12/favorable-media-coverage-somewhat-unlikely-to-impact-gw-pharmaceuticals-plc-gwph-stock-price.html.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Insider Buying and Selling by Quarter for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit